Global Duchenne Muscular Dystrophy Treatment Market to See Spectacular Growth by 2019, says GlobalData

Global Duchenne Muscular Dystrophy Treatment Market to See Spectacular Growth by 2019, says GlobalData

  • Duchenne Muscular Dystrophy (DMD) treatment market value to expand from approximately $8.2 million in 2014 to $990 million by 2019
  • Translarna, eteplirsen and drisapersen market entries to drive growth, contributing 85.6% to the DMD treatment arena by 2019, says analyst

LONDON, UK (GlobalData), 14 April 2015 - The global treatment market for Duchenne Muscular Dystrophy (DMD) will expand in value at a staggering Compound Annual Growth Rate (CAGR) of 160.5%, from approximately $8.2 million in 2014 to $990 million by 2019, says research and consulting firm GlobalData.

The company's latest report* states that this growth will occur across six major markets: the US, France, Germany, Italy, Spain and the UK. Combined, the five European countries will contribute 55.2% to the total market value by 2019, while the US will account for 44.8%.

According to Nikhilesh Sanyal, Ph.D., GlobalData's Analyst covering Immunology, the primary driver behind this impressive expansion will be the market entry of PTC Therapeutics' Translarna, Sarepta Therapeutics' eteplirsen, and BioMarin/Prosensa's drisapersen.

Sanyal says: "These mutation-specific drugs are expected to have a high price point due to their novelty, efficacy and orphan drug status, and will contribute 85.6% to the DMD treatment arena by 2019. While Translarna is expected to be the top-selling DMD drug by 2019, exon-51-skipping therapies drisapersen and eteplirsen will also be a hotspot for growth, thanks to their rapid clinical development and significant demand.

"Despite rapid developments in DMD therapeutics over the last five years, there remains a large unmet need among patients who are not amenable to these mutation-specific drugs, and who would benefit from effective disease-modifying therapies."

However, the analyst adds that drug developers will need to overcome a number of challenges to take advantage of this major opportunity.

Sanyal explains: "There is currently a lack of standardization for measuring clinical efficacy across all stages of DMD. While most studies use the change in the six-minute walk test as the primary clinical endpoint, this applies only to ambulant patients and therefore excludes non-ambulant individuals, as well as children under the age of five.

"Furthermore, the high cost of novel disease-modifying drugs means that their reimbursement by local health authorities and insurance companies may be prevented following their entry into the arena," the analyst concludes.

*OpportunityAnalyzer: Duchenne Muscular Dystrophy – Opportunity and Market Analysis to 2019

-ENDS-

-NOTES TO EDITORS-

This report provides annualized Duchenne Muscular Dystrophy (DMD) therapeutics market revenue, annual cost of therapies and forecasts for five years to 2019. The key topics covered include strategic product assessment, market characterization, unmet needs, research and development strategies, clinical trial design and implications for the DMD therapeutics market.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GlobalData's team of industry experts.

For further insights from the report, request our on-demand complimentary webinar, presented by Nikhilesh Sanyal, Ph.D., GlobalData's Analyst covering Immunology.

For guidelines on how to cite GlobalData, please see:http://www.globaldata.com/QuotingGlobalData.aspx

-ABOUT GLOBALDATA-

GlobalData is a leading global research and consulting firm offering advanced analytics to help clients make better, more informed decisions every day. Our research and analysis is based on the expert knowledge of over 700 qualified business analysts and 25,000 interviews conducted with industry insiders every year, enabling us to offer the most relevant, reliable and actionable strategic business intelligence available for a wide range of industries.

For more information, please contact our Press Office on +44 (0)1204 543 537 or at [email protected].

Gain access to our latest press releases and expert analysis on developments in your industry. Subscribe to our RSS feed for theHealthcare sector, or connect with us on:

Facebook | LinkedIn | Twitter

 

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.